Pion therapy at TRIUMF. Treatment results for astrocytoma grades 3 and 4: a pilot study

Goodman, George; Skarsgard, L. D.; Thompson, G; Harrison, Robert W.; Lam, Gabriel K. Y.; Lugate, C.

doi:10.1016/0167-8140(90)90045-x

Cited by 22 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This holds true for conventionally fractionated postoperative radiotherapy, as well as for hyperfractionated radiation schedules [3,12]. Other radiation modalities, such as the use of neutrons [8,16], of pions [7] or heavy ions [4] did not live up to expectations. Other radiation modalities, such as the use of neutrons [8,16], of pions [7] or heavy ions [4] did not live up to expectations.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy of glioblastoma multiforme

et al. 1998

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Radiotherapy of glioblastoma multiforme

et al. 1998

View full text Add to dashboard Cite

show abstract

“…In cases believed to have transformed from lower grade gliomas or when the region of enhancement was ill defined a more generous high dose volume usually incorporating the low density region was used. Eighty of these received Megavoltage x-ray therapy, but 34 cases were offered and agreed to receive pion radiation therapy at TRIUMF during the first five years of the dose escalation program when the pion-beam was avail- [10]. Pion therapy has provided similar survival results to conventional therapy, although the phase II1 trial is ongoing.…”

Section: Treatment Datamentioning

confidence: 99%

“…The subset of patients who received pion therapy behaved in a similar fashion to all other patients in this analysis. This does not include the whole experience with the pion treated patients at TRIUMF which has been conducted since 1982 and separately reported [10]. Other clinical approaches that are being explored include the use of hypoxic chemosensitization, localized accelerated radiotherapy (60 Gy in 30 fractions over three weeks) and the use of radioactive implantation for recurrent malignant glioma.…”

mentioning

confidence: 99%

The treatment of adult supratentorial high grade astrocytomas

Duncan¹,

Goodman²,

Ludgate³

et al. 1992

J Neuro-Oncol

View full text Add to dashboard Cite

From 1 January, 1982 until 31 December, 1987 260 adult patients were referred to the Cancer Control Agency of B.C. with high grade supratentorial astrocytomas. Multifocal disease on presentation was present in 17 cases (6.5%). Their survival is poor and whole brain radiotherapy is required. All other cases had unifocal disease, but eight did not receive radiotherapy. The 235 cases who received radiotherapy were subject to univariate and multivariate analyses according to extent of surgery, age, Kernohan and WHO grading, Karnofsky performance status, whole brain treatment, partial brain treatment, total dose and neuroret. Age is an extremely important predictor of survival (P approximately equal to 0). The pathologic appearance of glioblastoma (WHO grade) as well as the Karnofsky performance status were also important independent factors in predicting survival (P = 0.016, 0.027 respectively) on Cox multivariate analysis. Dose and neurorets were significant factors only in cases where the performance status was not recorded, suggesting that dose was selected according to the patient's condition and age. In this analysis it was found that localized radiation fields may be used rather than whole brain without jeopardizing survival.

show abstract

“…Currently this treat ment technique is investigated in several centers [7,45]. In some centers the application of pion therapy of malignant astro cytoma is under investigation [23,25], Using a 3-dimensional spot technique the accuracy of the beam alignment was repro ducible within 2 mm. From a base line dose of 40 Gy photons whole brain and 17.5 Gy pion boost, doses were escalated to 33 Gy pions localized to the primary tumor and the median survival improved from 198 to 436 days.…”

Section: Stereotactic Exrtmentioning

confidence: 99%

Radiation Therapy of Malignant Gliomas

Bamberg¹,

Hess²

1992

Oncol Res Treat

View full text Add to dashboard Cite

Besides local resection, external radiation therapy (EXRT) plays the major role in the treatment of malignant glioma. With postoperative EXRT, median survival is increased to 9-12 months for glioblastoma multiforme (GBM), as compared to 4-5 months after surgery alone (median survival for anaplastic astrocytoma (AA): 27 months – 3 years). The target volume should include 2 cm beyond that indicated by CT and MRI. For treatment planning computed tomography in treatment position is mandatory, and an individualized face mask for immobilization of the head should be used during the whole process of treatment planning and treatment delivery. With conventional fractionation, a total dose of 60 Gy seems to be adequate. There is no evidence that the application of higher total doses, of hyperfractionated XRT, of radiosensitizers or of fast neutron radiotherapy can improve treatment results. The role of high precision single-dose stereotactic irradiation and of brachytherapy is undefined. For both techniques, it seems difficult to control AA or GBM at the perimeter of the tumor which is a frequent site of failure. The use of the chlorethyl nitrosoureas (e.g. BCNU, ACNU) is the most effective and frequent form of chemotherapy for malignant glioma. Adding chemotherapy to postoperative radiotherapy leads to an increased percentage of 18-month survivors, but the improvement of median survival for the whole group of patients is within several weeks. Prognostic factors such as grade, performance status, and age may considerably influence treatment results and treatment strategies. In severely compromised patients, treatment time may be reduced by altered fractionation schemes, and chemotherapy seems to be debatable.

show abstract

Pion therapy at TRIUMF. Treatment results for astrocytoma grades 3 and 4: a pilot study

Cited by 22 publications

References 4 publications

Radiotherapy of glioblastoma multiforme

Radiotherapy of glioblastoma multiforme

The treatment of adult supratentorial high grade astrocytomas

Radiation Therapy of Malignant Gliomas

Contact Info

Product

Resources

About